This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Dementia in Alzheimer disease, atypical or mixed type비정형 또는 혼합형 알츠하이머병에서의 치매

Contents and key points
ItemDetails
A. Classification codesICD-10: F00.2 (G30.8†) — mental and behavioral axis code. Paired code: G30.8 (other Alzheimer disease) | Special Copayment Reduction: V810 (severe intractable disease, 5 years)
B. SynonymsAtypical dementia (Alzheimer type), atypical Alzheimer disease, mixed-type Alzheimer dementia, mixed Alzheimer-vascular dementia
C. Adult onsetYes — atypical phenotypes commonly present in the 50s to 70s; mixed type in old age.
1. HistoryDevelopment of the concept of atypical Alzheimer disease; description of posterior cortical atrophy (PCA), logopenic aphasia, and frontal variant; emergence of the mixed dementia concept.
2. CausesAtypical: atypical distribution of Alzheimer pathology; mixed: combined pathology such as Alzheimer + vascular, Alzheimer + Lewy body.
3. GeneticsAPOE ε4; APP and PSEN1 variants rarely reported in PCA; overlap of vascular risk genes in the mixed type.
4. General epidemiologyAtypical Alzheimer: about 5–10% of all AD; PCA is the most common atypical form; mixed dementia: about 20–40% of dementia in the elderly.
5. PathophysiologyAtypical: atypical distribution of tau pathology (predominantly parietal, occipital, and language cortex); mixed: coexisting Alzheimer + vascular or Lewy body pathology.
6. SymptomsPCA: predominant visuospatial impairment (visual agnosia, spatial neglect); logopenic aphasia type: impaired word finding and sentence repetition; frontal variant: executive function and behavioral changes; mixed type: a variety of non-cognitive symptoms intermixed.
7. SignsOccipito-parietal cortical atrophy in PCA; perisylvian atrophy in the logopenic type; accompanying vascular lesions in the mixed type.
8. ScreeningComprehensive neuropsychological testing when atypical symptoms (visuospatial impairment, language impairment, executive dysfunction) appear; amyloid PET.
9. DiagnosisConfirm AD pathology by amyloid PET/CSF; recognize atypical clinical phenotypes; exclude other causal pathologies.
10. TreatmentSame as typical Alzheimer; active management of vascular risk factors in the mixed type; rehabilitation specific to the atypical phenotype.
11. PrognosisAtypical forms progress rapidly; the mixed type tends to have a poor prognosis because of the combined pathological burden.
12. PreventionCombined management of Alzheimer + vascular risk factors; blood pressure and blood glucose control is especially important for preventing the mixed type.
13. ReferencesCrutch SJ et al. Lancet Neurol 2017 and 9 other references

1. History

In ICD-10, F00.2 (G30.8†) is a code encompassing dementia in "atypical or mixed type" Alzheimer disease, applied to cases with clinical features or combined pathology that do not correspond to the typical phenotypes of F00.0 (early onset) and F00.1 (late onset). F00.2 is the * code for G30.8† (other Alzheimer disease), and in the ICD-10 dual coding system describes, from the mental and behavioral aspect, atypical clinical entities that have Alzheimer pathology but do not fit the typical early-onset or late-onset classification.

Clinical recognition of atypical Alzheimer deepened in the 1980s–90s when posterior cortical atrophy (PCA) and the logopenic variant of primary progressive aphasia (logopenic variant PPA) were found to be due to Alzheimer pathology. In 1988, Frank Benson and colleagues described PCA as an independent syndrome, and subsequent pathological studies confirmed that most (about 85–90%) of this syndrome is due to Alzheimer neuropathology. For the logopenic variant of primary progressive aphasia as well, the strong association with Alzheimer pathology was formally described in the 2011 international linguistic variant PPA criteria.

The concept of mixed dementia developed from the observation in autopsy studies that a considerable proportion of elderly dementia patients have Alzheimer pathology together with vascular pathology or Lewy body pathology. Through studies such as the 2007 ADNI (Alzheimer's Disease Neuroimaging Initiative), it was confirmed that mixed pathology with coexisting biomarkers is more common in clinical studies than pure single pathology. Mixed dementia is now recognized as an important subtype of dementia in the elderly, and approaches targeting both the vascular and Alzheimer components are emphasized in clinical intervention.


2. Causes

F00.2 covers two clinical situations: ① an atypical clinical phenotype with underlying but non-typical Alzheimer pathology, and ② a mixed type in which Alzheimer pathology coexists with other pathology (vascular, Lewy body, etc.).

Main phenotypes of atypical Alzheimer

Posterior cortical atrophy (PCA) presents with selective decline in visuospatial processing, visual attention, and constructional ability, as Alzheimer pathology is preferentially distributed in the occipito-parietal cortex. Memory impairment is mild early on, and visual symptoms come to the fore. Owing to reduced visual cortex function, difficulty reading and writing, difficulty recognizing objects, and Bálint syndrome (oculomotor apraxia, simultanagnosia, optic ataxia) may occur.

Logopenic variant primary progressive aphasia (lvPPA) is a language-centered phenotype whose main symptoms are word-finding difficulty and impaired sentence repetition, with reduced verbal fluency and difficulty producing sentences. Most cases have underlying Alzheimer pathology (amyloid positive), and asymmetric atrophy of the perisylvian cortex is characteristic.

Frontal variant Alzheimer is rare, but because of tau pathology predominantly in the prefrontal cortex it shows clinical features similar to frontotemporal dementia, such as executive dysfunction, personality change, and social disinhibition. Alzheimer pathology can be confirmed by positive amyloid biomarkers.

Mixed dementia

In autopsy studies of elderly dementia patients, only about 30–40% have pure Alzheimer pathology alone, and about 20–40% show Alzheimer pathology together with cerebrovascular pathology (cerebral infarction, white matter degeneration, vascular dementia lesions). Coexisting Alzheimer + Lewy body pathology is also observed in about 20%. When a vascular component is present, it can lower the threshold for clinical expression of Alzheimer pathology and cause more severe cognitive decline.


3. Genetics

The genetic background of atypical Alzheimer does not differ greatly from that of typical Alzheimer. APOE ε4 is also identified as a risk factor in PCA, lvPPA, and the frontal variant. Pathogenic APP and PSEN1 variants have rarely been reported in PCA, suggesting it may be an atypical phenotype of familial EOAD. A hypothesis that tau gene (MAPT) polymorphisms may influence the regional distribution pattern of Alzheimer tau pathology has also recently been studied.

In mixed dementia, genes related to Alzheimer pathology (APOE, BIN1, etc.) and vascular risk genes (genes related to blood pressure and lipids) act in an overlapping manner. Cases in which CADASIL (cerebral autosomal dominant arteriopathy) due to NOTCH3 variants coexists with Alzheimer pathology have also been rarely reported.


4. General epidemiology

Atypical Alzheimer accounts for about 5–10% of all Alzheimer patients. PCA is the most common of the atypical phenotypes, accounting for about 5% in Alzheimer specialty clinics. PCA often overlaps with early-onset Alzheimer, so the mean age at diagnosis is about 59–65 years. About 50–70% of lvPPA is due to Alzheimer pathology, and the remainder to FTD-related TDP-43 or tau pathology.

Mixed dementia is very common in dementia in the elderly, and based on autopsy studies about 20–40% of dementia in the elderly has mixed pathology. Many patients who were clinically diagnosed with pure vascular dementia or pure Alzheimer dementia actually have mixed pathology. Mixed dementia is being diagnosed increasingly accurately as biomarker-based clinical research becomes widespread.


5. Pathophysiology

In atypical Alzheimer, the underlying amyloid pathology is the same as in typical Alzheimer, but the distribution of tau pathology shows an atypical pattern rather than the typical one (hippocampal and medial temporal lobe predominance). In PCA, tau NFTs accumulate early and intensively in the visual cortex, parietal cortex, and posterior association cortex. The cause of this atypical tau distribution has not yet been fully elucidated, but regional neural network vulnerability and differences in the intrinsic susceptibility of specific neural circuits are presumed to contribute.

In mixed dementia, Alzheimer amyloid and tau pathology and cerebrovascular pathology (microvascular damage, white matter ischemic changes, microinfarcts) accelerate cognitive decline synergistically. Cerebrovascular pathology brings forward the clinical expression of Alzheimer pathology, and when cerebral amyloid angiopathy (CAA) and Alzheimer parenchymal plaques coexist, the risk of cerebral hemorrhage and cognitive decline is doubled.


6. Symptoms

In PCA (posterior cortical atrophy), visuospatial processing impairment, reduced visual attention, visual agnosia (difficulty recognizing faces and objects), reading disorder (alexia), and constructional apraxia appear from early on. Memory impairment is relatively mild early on, and patients themselves mainly complain of visual difficulties. Because patients often visit an ophthalmologist first with complaints of blurry vision or being unable to see even after getting new glasses, diagnosis tends to be delayed.

In the logopenic variant (lvPPA), fluency is preserved, but the main symptoms are word-finding difficulty (anomia) and reduced sentence repetition ability (decreased phonological short-term memory). Early on, language impairment is in the foreground, while memory and visuospatial function are relatively preserved.

In the frontal variant, the main symptoms are executive dysfunction (difficulty planning and strategizing, reduced cognitive flexibility), apathy, impaired judgment, and disinhibition, making it clinically difficult to distinguish from frontotemporal dementia. Confirming Alzheimer pathology with amyloid biomarkers is essential.

In mixed dementia, the memory impairment of Alzheimer disease is intermixed with the focal neurological deficits, executive dysfunction, and emotional changes of vascular dementia. A combination of stepwise and gradual progression, or focal neurological signs such as dysarthria and gait disturbance appearing together with Alzheimer memory impairment, strongly suggests mixed dementia.


7. Signs

In PCA, brain MRI shows asymmetric or bilateral atrophy of the occipito-parietal cortex (superior parietal lobule, posterior association cortex), with mild medial temporal lobe atrophy. Hypometabolism of the posterior cortex is characteristic on FDG-PET. Diffuse cortical amyloid deposition is seen on amyloid PET.

In lvPPA, MRI characteristically shows cortical atrophy around the left Sylvian fissure (left temporo-parietal junction). FDG-PET shows hypometabolism in the corresponding area.

In mixed dementia, MRI shows white matter hyperintensities (Fazekas grade 3), cerebral infarct lesions, and microbleeds (multiple on SWI) together with Alzheimer-pattern medial temporal lobe atrophy. When cerebral amyloid angiopathy (CAA) is present, multiple cortical-subcortical microbleeds are observed.


8. Screening

In patients presenting with atypical symptoms (visuospatial impairment, language impairment, or executive dysfunction more prominent than memory impairment), Alzheimer pathology is suspected and comprehensive neuropsychological testing and amyloid biomarker assessment are performed. In patients with visual impairment or reading difficulty without an ophthalmologic cause, Alzheimer PCA is included in the differential diagnosis when MRI findings suggest posterior cortical atrophy.

In patients at risk of mixed dementia (history of cerebrovascular disease + cognitive decline), checking for coexisting Alzheimer pathology with plasma or cerebrospinal fluid biomarkers helps determine the direction of treatment.


9. Diagnosis

Diagnosis of atypical Alzheimer consists of three steps: ① recognition of an atypical clinical phenotype (predominance of cognitive symptoms other than memory), ② confirmation of Alzheimer pathology by amyloid PET or cerebrospinal fluid Aβ42 and p-tau, and ③ exclusion of other causes (prion disease, CJD, FTD, LBD, vascular pathology, etc.). Without amyloid PET or cerebrospinal fluid biomarkers (A+), it is difficult to make a definitive diagnosis of atypical Alzheimer.

Mixed dementia is diagnosed when the clinical criteria for Alzheimer disease are met and evidence of cerebrovascular disease (cerebral infarction, extensive white matter degeneration, CAA, etc.) is confirmed on neuroimaging. Clinical judgment is needed as to whether the two pathologies contribute independently or whether the vascular pathology plays a role in bringing forward the symptomatic expression of Alzheimer pathology.


10. Treatment

Drug treatment of atypical Alzheimer is the same as for typical Alzheimer, using cholinesterase inhibitors and memantine. Anti-amyloid monoclonal antibodies (lecanemab, donanemab) are applicable in the early stage when Alzheimer pathology has been confirmed. As non-pharmacological interventions, visual rehabilitation (low-vision aids, environmental modification) is recommended for PCA and speech therapy for lvPPA.

In mixed dementia, management of vascular risk factors (blood pressure, blood glucose, lipids, antithrombotic therapy) should be carried out alongside Alzheimer drug treatment. Blood pressure control, antiplatelet therapy (anticoagulation in cardioembolic stroke such as atrial fibrillation), and statin therapy contribute to suppressing progression of the vascular component.


11. Prognosis

Atypical Alzheimer tends to progress faster than typical Alzheimer. In PCA patients, falls and mobility impairment due to visual dysfunction appear early, and daily functioning declines greatly at an early stage. The frontal variant seriously affects family relationships because of abnormal social behavior. Mixed dementia has a poorer prognosis than single-pathology dementia, with faster functional decline and earlier institutionalization reported.


12. Prevention

As with typical Alzheimer, management of modifiable risk factors is the key to preventing atypical Alzheimer. For preventing mixed dementia, an integrated approach that manages Alzheimer risk factors and vascular risk factors simultaneously is most effective. Treatment of hypertension in midlife, diabetes control, smoking cessation, and exercise are known to reduce the risk of mixed dementia the most. When CAA is present, antithrombotic treatment is decided carefully, considering the increased risk of cerebral hemorrhage with anticoagulant use.


13. References

  1. Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170-178. DOI: 10.1016/S1474-4422(11)70289-7. PMID: 22265212.
  2. Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-1014. DOI: 10.1212/WNL.0b013e31821103e6. PMID: 21325651.
  3. Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562. DOI: 10.1016/j.jalz.2018.02.018. PMID: 29653606.
  4. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69(24):2197-2204. DOI: 10.1212/01.wnl.0000271090.28148.24. PMID: 18071141.
  5. Mesulam MM, Weintraub S, Rogalski EJ, et al. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. Brain. 2014;137(Pt 4):1176-1192. DOI: 10.1093/brain/awu024. PMID: 24574503.
  6. Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021;397(10284):1577-1590. DOI: 10.1016/S0140-6736(20)32205-4. PMID: 33667450.
  7. Mendez MF. Early-onset Alzheimer disease and its variants. Continuum (Minneap Minn). 2019;25(1):34-51. DOI: 10.1212/CON.0000000000000702. PMID: 30707185.
  8. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629. DOI: 10.1016/S1474-4422(14)70090-0. PMID: 24849862.
  9. van der Flier WM, Skoog I, Schneider JA, et al. Vascular cognitive impairment. Nat Rev Dis Primers. 2018;4:18003. DOI: 10.1038/nrdp.2018.3. PMID: 29446769.
  10. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. DOI: 10.1016/S0140-6736(24)01296-0. PMID: 39096926.